|
Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb |
Research Funding - MedImmune |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Seagen; Verastem |
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca/MedImmune; Celgene; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Verastem |
|
|
Research Funding - Aduro Biotech; Boehringer Ingelheim; MedImmune; Morphotek |
Travel, Accommodations, Expenses - MedImmune |
|
|
Consulting or Advisory Role - Aduro Biotech |
|
|
Employment - Aduro Biotech; Merck Sharp & Dohme (I) |
Stock and Other Ownership Interests - Aduro Biotech; Merck Sharp & Dohme (I); Onyx |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Leadership - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |